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Introduction: Cigarette smoke associated polycyclic aromatic 
hydrocarbons can induce key drug-metabolizing enzymes of cyto-
chrome P450 and isoforms of the glucuronyl transferases families. 
These enzymes metabolize several systemic therapies for lung can-
cer. Induction of these enzymes may lead to accelerated clearance 
with resultant impact on systemic therapy efficacy and toxicity in 
smokers compared with nonsmokers. This article reviews published 
literature regarding the influence of smoking as it relates to alteration 
of metabolism of systemic therapy in lung cancer.
Methods: A structured search of the National Library of Medicine’s 
PubMed/MEDLINE identified relevant articles. Data were abstracted 
and analyzed to summarize the findings.
Results: Studies that analyzed pharmacokinetic data were prospective. 
Smokers receiving erlotinib exhibited rapid clearance, requiring a higher 
dose to reach equivalent systemic exposure compared with nonsmok-
ers. Smokers receiving irinotecan also demonstrated increased clear-
ance and lower systemic exposure. There was no difference in clearance 
of paclitaxel or docetaxel in smokers. Chemotherapy-associated neu-
tropenia was worse in nonsmokers compared with smokers in patients 
treated with paclitaxel, docetaxel, irinotecan, and gemcitabine.
Conclusions: Systemic therapy for lung cancer has a narrow ther-
apeutic index such that small changes in plasma concentrations or 
exposure in smokers may result in suboptimal therapy and poor 
outcomes. Smoking cessation must be emphasized at each clinical 
visit. However, prospective trials should take into consideration the 
effects of smoking history on drug pharmacokinetics and efficacy. 
The metabolizing enzyme phenotype in smokers may require indi-
vidualized dose algorithms for specific agents.
Key Words: Pharmacokinetics, Pharmacodynamics, Smoking, 
Chemotherapy metabolism, Nicotine, Response, Toxicities, Lung cancer
(J Thorac Oncol. 2014;9: 917–926)
Cigarette smoking is a significant source of morbidity and mortality. According to the National Health Interview 
Survey, approximately one in five (20.2%) of US adults cur-
rently smoke.1 In addition, there is an estimated 49.9 million 
former smokers in the United States.2 Smoking is the greatest 
risk factor for lung cancer, which continues to be the lead-
ing cause of cancer-related death for both sexes.3 Outcomes in 
lung cancer for both current and former smokers are dismal, 
with a 5-year relative survival rate of approximately 15%.4 It is 
also evident that nonsmokers have an improved survival from 
therapy for advanced lung cancer compared with smokers.4–6 
The recent Surgeon General Report  highlights 50 years of 
progress in tobacco control and prevention and presents new 
data on the health consequences of smoking. This may relate 
to a multitude of factors ranging from intrinsic differences in 
lung cancer biology, host associated medical comorbidities7 
and polymorphisms in drug-metabolizing enzymes8 leading to 
reduced efficacy of therapies.
In addition to the carcinogenic effects of tobacco prod-
ucts, the components of cigarette smoke can induce drug-
metabolizing enzymes, which have been demonstrated in both 
in vitro and animal models.9–11 Induction of these metabolizing 
enzymes resulting in accelerated clearance may reduce drug 
efficacy in smokers and impact clinical outcomes. Smoking is 
associated with reduced beta blocker effectiveness, in terms of 
lowering blood pressure and heart rate, and reduced sedation 
from benzodiazepines.12 Several often used chemotherapeutic 
drugs and many of the newer targeted therapies are metabo-
lized by the hepatic cytochrome P450 enzymes, in addition to 
the uridine 5′-diphosphate-glucuronyl transferases. Although 
the exact mechanism behind the accelerated drug metabolism 
has not yet been clearly elucidated, there is emerging evidence 
that compounds in cigarette smoke may epigenetically modify 
these enzymes that result in persistently elevated activity, even 
after smoking cessation.13 In addition, there may be a direct 
effect of nicotine on molecular effectors of cellular apoptosis 
induced by several chemotherapies for lung cancer.14
Several studies have reported the effects of cigarette 
smoking on the ,pharmacokinetic (PK) and pharmacodynamic 
(PD) effects of systemic for lung cancer. The goal of this arti-
cle is to review the effects of cigarette smoke as it relates to 
metabolism and efficacy of systemic therapies for lung can-
cer. We searched PubMed/MEDLINE to identify relevant arti-
cles published between 2000 and January 2014. The search 
strategy included Medical Subject Headings (MeSH) and 
keywords representing the concepts of smoking status, smok-
ing cessation or nicotine replacement combined with MeSH 
and keywords for lung cancer, chemotherapy, and selected 
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chemotherapeutic agents (docetaxel, gemcitabine, etc.). 
Citations were filtered to exclude citations solely on “never 
smokers,” and then filtered again using MeSH, subheadings, 
and keywords to identify articles that focused on molecular 
rather than metabolic or pharmacokinetic responses to che-
motherapy. Data were abstracted from 171 publications and 
summarized below.
EFFECTS OF CIGARETTE SMOKE ON PHASE I 
AND II METABOLIZING ENZYMES
Cigarette smoke is known to contain more than 7000 
chemicals, of which more than 60 possess carcinogenic prop-
erties.2 Smoke is composed of both volatile and particulate 
phases that comprise approximately 95% and 5%, respec-
tively. The volatile phase is composed primarily of nitrogen, 
oxygen, and carbon dioxide.15 Excluding the alkaloid and 
the water content, the remaining particulate mass is referred 
to as tar, which is composed of carcinogens including poly-
cyclic aromatic hydrocarbons (PAHs), N-nitrosamines, and 
aromatic amines.16 PAHs are compounds with two or more 
aromatic and cyclic rings that can induce DNA mutations.17,18 
More than 500 PAHs have been identified in cigarette 
smoke.19 PAHs are oxidized by cytochrome P450 enzymes 
and the resultant metabolites exert mutagenic effects on 
DNA. The same PAHs have also been shown to induce mem-
bers of the P450 enzyme family, which normally process 
xenobiotics.15,20,21 The P450 enzymes are responsible for 
phase I drug metabolism by oxidizing the parent compound 
to a more readily excreted metabolite.22 The most common 
isoforms as relates to metabolism of often used systemic 
therapy for lung cancer include CYP1A1/2, CYP2D6, and 
CYP3A4. Herein, we will review how tobacco smoke inter-
acts with these enzymes either through increased induction 
or increased degradation.
CYP1A1 and CYP1A2 are the most common CYP1 
family isoforms that metabolize some systemic therapies used 
to treat lung cancer such as erlotinib, an epidermal growth 
factor (EGfR) inhibitor. PAHs in tobacco smoke can induce 
isoenzymes CYP1A1 and CYP1A2.20 Zhu et al.23 theorized 
that the process of selective induction of a CYP isoform by 
PAHs is primarily determined by the following three core ele-
ments: each inducible CYP isoform has a corresponding intra-
cellular receptor that interacts with the inducer chemicals, 
each isoform and its receptor may share highly similar steric 
structures, and each inducible CYP gene may have a distinct 
genomic response element that interacts selectively with the 
corresponding receptor. The CYP1A1 enzyme, an aryl hydro-
carbon hydroxylase, is involved in the activation of procar-
cinogens, such as PAHs, and can be transcriptionally induced 
by PAHs.24,25 Binding to the aryl hydrocarbon receptor, a basic 
helix-loop-helix transcription factor, leads to heterodimer-
ization and binding to the aryl hydrocarbon-responsive ele-
ments in the CYP1A1 gene,26 as detailed in figure 1A. These 
events then lead to increased expression of the CYP1A1 gene 
and potentially accelerated drug metabolism.27,28 Anttila et 
al.29 observed smoking-related alterations of the CYP1A1 
promoter methylation status in lung tumor samples. DNA 
from resected lung tumors demonstrated complete or partial 
CYP1A1 promoter methylation in 33% of heavy smokers, 
71% of light smokers, and 98% of nonsmokers.29
Similarly, CYP1A2 is a hepatic enzyme that is respon-
sible for the metabolism of several often used medica-
tions, such as theophylline, caffeine, and acetaminophen.12 
Induction of CYP1A2 may be mediated through binding 
of PAHs similar to CYP1A1, which leads to transcriptional 
activation of the CYP1A2 gene.30 Alternatively, as detailed in 
figure 1B, PAH can epigenetically modify transcription fac-
tors such as NHf4α and HNf1α, which leads to the upregu-
lation of CYP1A2.31,32 Cigarette smoke induces chromatin 
remodeling by acetylating lysine residues on histone proteins 
to facilitate gene expression.33 In Addition, the activity of 
histone deacetylases, which remove acetyl groups to repress 
transcription were reduced activity in bronchial biopsies from 
smokers compared with nonsmokers (p < 0.01).34 Induction of 
CYP1A2 is linked to increased activity of the enzyme which 
in turn leads to reduced serum concentrations and reduced 
efficacy of the substrates.35
CYP2D6, the most common isoform of the CYP2 fam-
ily, is involved in metabolism of opiates used in supportive 
care for lung cancer patients. The gene encoding this enzyme 
has been reported to have multiple single nucleotide polymor-
phisms (SNPs) that can lead to varying expression among the 
FIGURE 1.  PAH-induced direct (A) transcriptional and (B) epi-
genetic regulation of cytochrome P450 enzymes, CYP1A1, and 
CYP1A2. PAH, polycyclic aromatic hydrocarbon; Ah, aryl hydro-
carbon; ARNT, aryl hydrocarbon receptor nuclear translocator; 
Hsp90, heat shock protein 90; XAP2, X-associated protein.
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population. These different SNPS are associated with spe-
cific phenotypes namely extensive metabolizers, ultra rapid, 
and slow metabolizers. Approximately, 7.5% of Europeans 
and white Americans are slow metabolizers, whereas <2% of 
Asians and African Americans are slow metabolizers. Other 
isoforms such as CYP2E1, which biotransforms many com-
pounds, including clinical drugs such as acetaminophen is 
also induced by nicotine leading to lower plasma concentra-
tions of CYP2E1 substrates.36
CYP3A4 is the most abundant P450 isoform in the liver 
and gut and responsible for the metabolism of several often 
used drugs and systemic therapies for lung cancer, including 
the taxanes, gefitinib, and erlotinib. This increase in transcrip-
tion leads to increased activity of the enzymes which in turn 
can affect PK of drugs metabolized by the CYP3A4 isoform. 
Examples include erlotinib as discussed below. PAHs are 
also known to induce some isoforms of the uridine diphos-
phate glucuronyltransferase family, which includes Phase II 
drug-metabolizing enzymes responsible for glucuronic acid 
conjugation.12 Studies have shown increased glucuronidation 
rates of drugs such as codeine and propranolol in smokers.37,38 
Summarizing, cigarette smoke can lead to increased activa-
tion of several phase I and II drug-metabolizing enzymes. The 
increased activation may be related to direct transcriptional or 
epigenetic regulation by the PAHs present in smoke.
PK AND PD EFFECTS RELATED TO INDUCTION 
OF METABOLIZING ENZYMES
Induction of the cytochrome P450 enzymes and the 
glucuronyl transferases has a direct impact on both PK 
and PD parameters related to drugs metabolized by these 
enzymes. Some of the most clinically significant PK interac-
tions between various nonchemotherapeutic drugs and smok-
ing have been detailed in a review by Kroon,39 who notes that 
caffeine, clozapine, olanzapine, and fluvoxamine all exhibit 
significant alterations to PK properties with cigarette smoke 
exposure, suggesting that smoking history must be taken into 
account when designing treatment plans. Similarly, smoking 
has been shown to cause PD drug interactions with hormonal 
contraceptives and inhaled corticosteroids.40,41 Thus, although 
the exact mechanism of accelerated metabolism has not yet 
been clearly elucidated in all cases, it can be hypothesized 
that it may be because of both direct transcriptional effects 
of smoking on the CYP isoenzymes as described above or 
epigenetic effects on these enzymes, which keep them persis-
tently activated for some time, even after smoking cessation.42
Short term we know that for the enzyme to be induced 
by cigarette smoke, additional amounts of the enzyme must 
be produced. Once the inducing agent has been discontinued, 
these enzymes continue to be induced because they do not 
simply cease to exist. Therefore, it is not until these enzymes 
have run their natural lifespan that we begin to see CYP 
metabolism return to normal.43 In addition, new data emerging 
suggest that epigenetic effects of smoking may have a greater 
impact on sustained induction of CYP enzymes. Currently, 
there are no data to parse out whether cigarette smoke associ-
ated induction of P450 enzymes is transcriptional, epigenetic, 
or a combination thereof. Regardless, it has been posited that 
smokers prescribed certain medications that are substrates to 
the P450 enzymes may require a higher dose than nonsmokers 
and, conversely, may require dose reduction upon cessation of 
smoking.12
EFFECTS OF NICOTINE ON SYSTEMIC THERAPY 
FOR LUNG CANCER
Nicotine, an alkaloid, is considered to be the addic-
tive component of tobacco. Cotinine, the main metabolite of 
nicotine, has been shown to be a reliable marker of nicotine 
exposure and more reflective of recent rather than acute nico-
tine use, which provides a better assessment of baseline nico-
tine exposure.44 There are no prospective studies describing 
the effects of nicotine or nicotine derivatives on alteration of 
metabolism of systemic therapies for lung cancer. The litera-
ture, however, is rife with studies that demonstrate that nico-
tine affects various signaling pathways in lung cancer that are 
associated with resistance to chemotherapy used to treat lung 
cancer. Nicotine binds to high-afﬁnity nicotine acetylcho-
line receptors (nAChRs) that are found on both normal and 
malignant human lung cells.45–47 After binding to the nAChR, 
nicotine can stimulate multiple signaling pathways including 
the RAS pathway, leading to increased cellular proliferation. 
In addition, nicotine inhibits apoptosis in various cells lines, 
suggesting that nicotine has the ability not only to promote 
lung cancer development by activating cell growth pathways, 
but also to reduce the efﬁcacy of chemotherapeutic agents by 
stimulating survival pathways.48–50 It has been postulated that 
nicotine-induced resistance to proapoptotic chemotherapy 
occurs through modulation of mitochondrial signaling51,52 
Nicotine prevented chemotherapy-induced reduction of mito-
chondrial membrane potential, activation of caspase-9, and 
translocation of Bax to the mitochondria. In addition, AKT-
mediated phosphorylation of proapoptotic protein Bad, and 
upregulation of antiapoptotic protein, XIAP, was observed in 
cells exposed to nicotine.51,53 Inhibition of mitogen-activated 
protein kinase and AKT prevents the antiapoptotic effects 
of nicotine and decreased chemotherapy-induced apoptosis. 
Others have demonstrated that combined exposure to nicotine 
and cigarette smoke carcinogen, nicotine-derived nitrosamine 
ketone, for a week augmented Bcl-2 expression and increased 
resistance to cisplatin-mediated apoptosis.54 More recently, 
it has also been shown that other than these direct effects, 
nicotine and its derivatives can stimulate the release of stress 
hormones from cancer cells, leading to increased cancer cell 
proliferation.55
There are no human studies directly studying the effects 
of nicotine on chemotherapy effects or toxicities. A detailed 
discussion on molecular effects of nicotine as relates to lung 
cancer signaling pathways is beyond the scope of this article 
and the reader is referred to recent reviews that provide com-
prehensive analysis of the literature.50,56,57 We will limit this 
review to direct effects of smoking on metabolism of often 
used systemic therapy for lung cancer.
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EFFECT OF SMOKING ON SYSTEMIC THERAPY 
FOR LUNG CANCER
The literature investigating the effect of tobacco smoke 
on the catabolism of commonly used chemotherapeutic agents 
is relatively limited, especially drugs used to treat lung cancer. 
Given the known association of smoking with lung cancer, 
a review of this interaction and effect is both necessary and 
clinically relevant. Moreover, although this interaction has 
been investigated with a small number of chemotherapeutic 
agents, the effects of drug efficacy and outcome have not yet 
been clearly delineated for many drugs. A more clear under-
standing of mechanism, effects, and outcome may allow clini-
cians to tailor chemotherapy drug choice according to known 
factors, including whether the patient is a current, former, or 
never smoker.
ERLOTINIB
Erlotinib is an orally active potent selective inhibitor of 
the epidermal growth factor receptor (EGfR) tyrosine kinase. 
Erlotinib inhibits EGfR-dependent proliferation of tumor 
cells in vitro and blocks cell cycle progression in the G1 
phase.58,59 Erlotinib is predominately metabolized by CYP3A4 
and a lesser extent by CYP1A2 and CYP1A1 enzymes involv-
ing demethylation of side chains and oxidation to carboxylic 
acid metabolites.60 Cigarette smoking can accelerate catabo-
lism and result in lower plasma concentrations of erlotinib.
Studies have demonstrated variability in survival for 
lung cancer patients receiving erlotinib based on smoking sta-
tus. In a retrospective analysis of 88 patients with advanced 
non–small-cell lung cancer (NSCLC) who received erlotinib 
or pemetrexed as second-line therapy, erlotinib achieved signif-
icantly better progression-free survival (PfS) in never smokers 
when compared with former smokers (3.5 versus 2.7 months, 
p = 0.005).61 Similarly, never smokers with squamous histol-
ogy receiving erlotinib lived longer compared with ever smok-
ers.62 Moreover, in a comparative analysis of the efficacy of 
second-line docetaxel and erlotinib treatment in patients with 
advanced NSCLC, heavy smoking history in erlotinib-treated 
patients was associated with decreased overall survival (hazard 
ration [HR] 3.61 [1.77–7.4], p = 0.0005).63 In the phase III trial 
by Shepherd et al.64 entitled BR.21, smoking history was the 
only clinically relevant factor showing interaction with erlo-
tinib treatment, indicating that erlotinib was more effective in 
patients who had never smoked, when compared with patients 
who were either current or former smokers. Specifically, 24.7% 
of never smokers had complete or partial responses to ther-
apy versus 3.9% of current or ever smokers (p < 0.001). The 
median survival for patients on erlotinib that never smoked was 
12.3 months (HR 0.42), former smokers 5.5 months (HR 0.84), 
and current smokers 6.1 months (HR 0.93) (p < 0.006).64–66 
It is true that many nonsmoking related lung adenocarcinoma 
that respond to EGfR-targeted tyrosine kinase inhibitors have 
an activating mutation in the EGFR gene. However, pharma-
cokinetically, current smokers had nearly a twofold reduction 
in measured trough erlotinib plasma levels compared with 
former and never smokers at 24 hours postdose,65 which sug-
gests that factors other than EGfR mutation status may result 
in altered drug response. Lu et al.67 analyzed data from seven 
erlotinib clinical trials in which erlotinib was administered at 
150 mg once daily; the primary objective of the study was to 
characterize the PK of erlotinib in patients with solid tumors 
and identify factors that had an impact on PK. PK data were 
available for 1047 of 1859 (56%) of patients randomized to 
treatment with erlotinib in the seven trials evaluated. Current 
smokers had median steady-state erlotinib trough plasma con-
centrations (C
24h
) approximately half that of patients who were 
former smokers. furthermore, smoking status was found to be 
a significant covariate affecting drug clearance. Current smok-
ers had a 23.5% increase in clearance compared with never and 
former smokers. Thus, the result of smoking effect on clear-
ance was consistent with in vitro data that demonstrated induc-
tion of CYP enzymes by cigarette smoke.12
To better evaluate the question whether the decreased 
erlotinib exposure seen in current smoking cancer patients 
versus former or never smokers was because of their smok-
ing status, Hamilton et al.68 designed a phase I, single-center, 
open-label PK crossover study. The study enrolled 32 male 
subjects, both nonsmokers (defined as subjects who had not 
consumed tobacco or nicotine-containing products for 1 year 
before the start of the study) and current smokers (defined as 
having smoked a minimum of 10 cigarettes per day for greater 
than or equal to 1 year and have a positive test for cotinine). 
All subjects received a single dose of 150 mg erlotinib on day 
1 followed by a single dose of 300 mg erlotinib on day 15. 
Eleven plasma sampling times were used to determine the PK 
profile for each subject, and PKs of each cohort were com-
pared. Results showed that smokers experienced decreased 
exposure to erlotinib when compared with nonsmokers; both 
the analytes of erlotinib and OSI-420 (the main metabolite of 
the drug) were eliminated more rapidly in smokers than non-
smokers, and the dose to reach an area under the concentration 
curve (AUC) in the therapeutic range was 300 mg for smokers 
versus 150 mg for nonsmokers. The ratio of AUC for smokers 
to nonsmokers was 35.9% (p < 0.0001) and ratio of 24-hour 
concentration was 12.1% (p = 0.0001). In addition, this study 
found that the C
max
 of smokers was approximately two-third 
of that of nonsmokers and the C
24h
 of smokers was 8.3-fold 
lower than that of nonsmokers. These findings confirmed 
that smoking does alter the PK of erlotinib with decreased 
plasma concentrations and increased clearance in smokers. It 
was hypothesized that these findings may be due, in part, to 
induction of the cytochrome P450 CYP1A1 and CYP1A2 iso-
forms by cigarette smoke, leading to increased catabolism and 
clearance. The clinical implications are also important to note 
that nonsmokers had a higher incidence of adverse events, 
including rash and diarrhea, than current smokers, possi-
bly indicating increased erlotinib exposure compared with 
the smoker cohort. Conversely, studies have also shown that 
smokers receiving erlotinib have increased CYP1A1 mRNA 
in the lungs, which then generate reactive quinone-imine and 
epoxide intermediates, exhausting cellular glutathione stores, 
and leading to increased interstitial lung disease.69 Li et al.69 
showed that smokers receiving another EGfR inhibitor gefi-
tinib had a 12-fold increase in glutathione adduct formation 
compared with nonsmokers, consistent with an upregulation 
of CYP1A1 in pulmonary microsomes (Table 1). Similarities 
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between gefitinib and erlotinib metabolism has been reviewed 
by Duckett and Cameron.70 Based on PK findings and clini-
cal implications, the possibility of dose escalation of erlotinib 
remains a viable option.
A recent study determined maximum-tolerated dose 
(MTD) in smokers and compared PK profiles with standard 
dosing.71 In the first part of the study, a standard dose esca-
lation study was performed in a cohort of patients receiving 
200–350 mg of erlotinib per day, escalating in 50 mg incre-
ments. Patients were monitored for dose-limiting toxicities 
while taking the drug for 14 days. The Phase I component of 
the study determined that the MTD for smokers was 300 mg 
per day. In the Phase II portion, the PK and toxicity profile 
for smokers receiving 300 mg daily was found to be similar to 
nonsmokers receiving 150 mg daily, which confirmed that cur-
rent smokers both have increased clearance and tolerate dose 
escalation. Based on these findings, this study concluded that 
the recommended Phase II dose of erlotinib was 300 mg for 
current smokers. Moreover, an exploratory survival analysis 
also noted a trend towards longer median survival for smokers 
receiving the escalated dose of erlotinib.
Additional prospective studies are required to determine 
whether an increased dose of erlotinib in smokers without an 
activating mutation of EGfR affects survival outcomes. It is 
also unclear whether EGfR-wild type patients may be targeted 
by increasing the half maximal inhibitory concentration (IC
50
) 
of EGfR inhibitors and such studies are also underway.72 A 
prospective study by Petty et al.59 revealed that smoking sta-
tus was associated with a higher MTD of erlotinib; however, 
this increased dose did not favorably affect PfS. In summary, 
the use of erlotinib in advanced lung adenocarcinoma is cur-
rently approved for patients with an activating EGfR muta-
tion. The recently completed ERMETIC study demonstrated 
that patients with identified EGfR mutation had better out-
comes with erlotinib.73 However, there is ample data that a 
small subset of patients with wild-type EGFR genes may also 
respond to erlotinib, albeit to a lesser extent.74,75 Although 
the magnitude of PfS improvement was not as great as those 
patients with EGfR mutations, for this group of patients, one 
could consider differential dosing of erlotinib based on smok-
ing status. The most crucial intervention is smoking cessa-
tion. However, consideration may be given to altered PKs of 
erlotinib in patients who have recently quit smoking, yet still 
demonstate increased cytochrome P450 isoforms.
TAXANES
Taxanes are used as a first-line treatment of NSCLC, 
often with a platinum compound. Both docetaxel and pacli-
taxel are antimicrotubule agents metabolized by CYP3A and 
CYP2C8.76,77 Prior studies have suggested that the PKs of 
paclitaxel are greatly influenced by external factors, including 
environmental and genetic factors. To determine the effects 
of smoking on the PK and toxicity profiles of both docetaxel 
and paclitaxel tumors, de Graan et al.78 conducted a retro-
spective study of 566 patients with solid tumors enrolled in 
multiple studies conducting PK analyses. Docetaxel-treated 
patients received 75–100 mg/m2 dose, and paclitaxel-treated 
patients received 90 mg/m2 weekly or 175 mg/m2 every 
3 weeks. Upon analysis of PK parameters (calculated by non-
linear mixed effect modeling population analysis), cigarette 
smoking was not found to alter the PK determinants of either 
drug, but smokers treated with docetaxel and paclitaxel were 
found to have lower incidence of neutropenia and leukopenia. 
Specifically, smokers treated with docetaxel showed less grade 
4 neutropenia (35% versus 52%; p = 0.01) than nonsmokers. 
Smokers treated with paclitaxel had less grade 3-4 leukopenia 
than nonsmokers (12% versus 35%; p = 0.03) and the white 
blood cells nadir was lower in nonsmokers (median 2.7 × 109/L; 
range 0.05–11.6 × 109/L) than in smokers (median 3.3 × 109/L; 
range 0.8–10.2 × 109/L; p = 0.02). The study investigators 
concluded that further research was warranted to clarify the 
underlying mechanisms of this potential protective effect of 
smoking on hematologic toxicities in taxane therapy. Other 
studies have shown that it is the time above paclitaxel plasma 
TABLE 1.  Potential Pharmacokinetic and Pharmacodynamic Effects of Smoking-induced Induction of Drug-Metabolizing 
Enzymes in Often Used Systemic Therapy in Lung Cancer
Drug
Area Under 
Curve C
max
CL Enzymes Drug Target Reactive Intermediates Adverse Reactions
Erlotinib ↓ ↓ ↑ CYP3A4, CYP1A2,  
and CYP1A1
HER1/EGfR Quinone-imines  
epoxides
↓Rash, diarrhea 
↑DILI*, ILD†, SJS
Docetaxel NC NC NC CYP3A4 Antimitotic — ↓Neutropenia, anemia, 
thrombocytopenia, alopecia
Paclitaxel NC NC NC CYP3A4 and CYP2C8 Antimitotic — ↓Neutropenia, anemia, 
thrombocytopenia, alopecia
Irinotecan ↓ ↓ ↑ UGT1A1 and CYP3A Topoisomerase-I inhibitor — ↓Neutropenia, leukopenia, diarrhea
Gemcitabine U U U Cytidine deaminase Cytidine analogue — ↓Neutropenia
Gefitinib ↓ ↓ ↑ CYP3A4, CYP1A2,  
and CYP1A1
HER1/EGfR Quinone-imines  
epoxides
↓Rash, diarrhea ↑DILI, ILD‡
Increase in parameter in represented by ↑ and decrease by ↓.
*DILI, drug-induced liver injury.
†ILD (interstitial lung disease), increased ILD because of increased CYP1A1 mRNA in lungs generating the reactive intermediate, exhausting cellular glutathione stores.69
‡ILD (interstitial lung disease), 12-fold increase in glutathione adduct formation in smokers compared with nonsmokers. This increase is consistent with an upregulation of 
CYP1A1 in pulmonary microsomes from smokers.9
CL, clearance; NC, no change; SJS, Stevens-Johnson syndrome; U, unknown.
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concentration of 0.05 to 0.2 μmol/l (t
c > 0.05–0.2
) is a better predic-
tor of treatment-related neutropenia than clearance.79 In sum-
mary, smokers treated with taxanes seem to have less grade 
3/4 severe neutropenia. The exact reasons for this are unclear; 
further studies are needed to determine whether a lesser degree 
of neutropenia is a pharmacodynamic (PD) predictor of poor 
response to taxanes in smokers with advanced NSCLC.
IRINOTECAN
The constituents of tobacco smoke have similarly been 
found to alter the PK and adverse effects of irinotecan (CPT-
11), a topoisomerase-I inhibitor that is approved for treatment 
of small-cell lung cancer. Irinotecan is a known substrate for 
several cytochrome P450 and UGT1A1 isoenzymes, which 
are known to be induced by tobacco smoke. In addition, in 
phase I studies, most responses to irinotecan were observed at 
the highest dose levels, indicating a clear-dose response rela-
tionship with this drug.80 In vitro studies have demonstrated 
that smoking may affect the partitioning of irinotecan in red 
blood cells (RBCs).81 Dumez et al.81 performed in vitro incu-
bations of blood from both smoker and nonsmoker volunteers 
with irinotecan over a concentration gradient to investigate the 
changes in partitioning between RBCs. After extraction and 
sample pretreatment, high-performance liquid chromatogra-
phy and fluorescence detection were used to determine drug 
concentration in the different blood consitutents. Although 
irinotecan generally showed relatively high affinity for the 
RBCs, there was a higher concentration of irinotecan in the 
erythrocytes of nonsmokers when compared with smokers. 
It was theorized that constituents of tobacco smoke, such as 
arylamines, directly prevented RBCs from interacting with 
irinotecan. Because RBCs play a key role in drug transport 
because of their long lifetime, higher drug concentrations in 
nonsmokers versus smokers may have clinical implications.
To better investigate the potential clinical effect of smok-
ing on irinotecan PKs, van der Bol et al.82 reviewed the data of 
202 patients who received irinotecan through nine prospective 
trials between 1996 and 2005. Patients received irinotecan once 
every 3 weeks as a 90-minute intravenous infusion at doses 
ranging from 175 to 350 mg/m2 or a 600 mg flat dose. Blood 
samples were collected at set time points up to 500 hours after 
the infusion for measurements of irinotecan and its metabo-
lites, SN-38 and SN-38G. Samples were analyzed by high-
performance liquid chromatography. A total of 190 patients 
(49 smokers and 141 nonsmokers) were assessable to evaluate 
the effect of smoking on the PK properties of irinotecan. The 
dose-normalized area under the plasma concentration-time 
curve of irinotecan was significantly lower in smokers than in 
nonsmokers. Smokers also showed an 18% faster clearance of 
irinotecan than nonsmokers (median, 34.8 versus 29.5 l/hour, 
p = 0.001) and 40% lower systemic exposure to the active iri-
notecan metabolite SN-38 when compared with never smok-
ers. Notably, a specific exclusion criterion for the analysis was 
the use of known CYP3A or UGT1A1 inducers or inhibitors, 
thereby reducing potential confounding metabolic phenotypes. 
The analysis also revealed that smokers who received irino-
tecan were found to experience significantly less hematologic 
toxicity, including considerably less neutropenia. Specifically, 
the median white blood cell values decreased to 5.3 × 109/l in 
smokers and 3.0 × 109/l in nonsmokers (p < 0.001); the respec-
tive absolute neutrophil count values were 3.3 × 109/l versus 
1.6 × 109/l (p < 0.001). The authors concluded that smoking 
significantly affects the PK and toxicity profile of irinotecan. It 
was posited that the more extensive glucuronidation of SN-38 
in smokers resulted in reduced systemic exposure to the active 
metabolite, thereby likely contributing to less hematologic tox-
icity. Although the exact underlying mechanism remains to be 
elucidated, the effects of smoking on irinotecan PK may be 
ascribed to induction and modulation of CYP3A and UGT1A1 
enzymes, which are involved in irinotecan metabolism. In sum-
mary, reduced exposure to irinotecan is seen in current smok-
ers. However, it is unclear whether this affects responsiveness 
of lung cancer to irinotecan.
GEMCITABINE
Gemcitabine is a prodrug, a deoxycytidine analogue 
that requires intracellular uptake and phosphorylation to be 
activated. The drug is phosphorylated to gemcitabine mono-
phosphate (dfdCMP) by deoxycytidine kinase, which is then 
converted to the active metabolites, gemcitabine di- and tri-
phosphate nucleosides (dfdCDP and dfdCTP). This nucleo-
side analogue exhibit cytotoxic effects through inhibition of 
DNA synthesis. Gemcitabine is inactivated by cytidine deami-
nase (CDA) mediated conversion to the inactive metabolite, 
difluorodeoxyuridine (dfdU).83
Gemcitabine has been studied extensively as both a single 
agent and in combination with a platinum-based compound in 
both first and second-line setting for lung cancer.84–87 In these 
studies, doses ranged from 800 to 1200 mg/m2 weekly admin-
istered for 3–4 weeks. Gemcitabine is fairly well tolerated, with 
the principal hematologic toxicity being grade 3/4 neutrope-
nia in 10–20% of patients. The overall response rate in nearly 
600 assessable patients was 21%.88 The recommended dosage 
regimen for gemcitabine monotherapy is 1000 mg/m2 doses 
administered over 30 minutes on days 1, 8, and 15. CDA is a 
key enzyme in gemcitabine metabolism. Previous studies have 
shown SNPs in the CDA gene that may affect the PK and toxic-
ity of gemcitabine.89 However, the indentified SNPs occur in low 
allele frequencies and are unlikely to explain the entire story.90 
Although little is known regarding the effect of smoking on its 
PK in vivo, smoking has been shown to increase the expression 
of CDA.91 This overexpression may lead to increased catabolism 
and reduced efficacy of the drug in smokers and former smokers.
Kanai et al.92 performed a retrospective review of 
103 patients receiving gemcitabine monotherapy at Kyoto 
University Hospital over a 4-year period and obtained infor-
mation regarding smoking history and incidence of grade 3–4 
gemcitabine-induced neutropenia from the medical record. 
Gemcitabine was initiated at doses of 460–1000 mg/m2 over 30 
minutes on days 1, 8, and 15 of a 28-day cycle. Logistic regres-
sion analysis was carried to out to investigate the correlation 
between gemcitabine-induced neutropenia and various clini-
cal factors, including smoking history. Of the 103 patients, 51 
were smokers (current and former smokers) and 52 nonsmok-
ers. Overall, smokers were found to have a lower incidence 
of grade 3–4 neutropenia as nonsmokers (24% vs. 56%; odds 
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ratio 0.244, 95% confidence interval 0.105–0.569; p < 0.001). 
After logistic regression analysis, smoking emerged as an inde-
pendent inverse predictor of gemcitabine-induced neutropenia 
(odds ratio 0.188, 95% confidence interval 0.057–0.618; p = 
0.006). In addition, dose intensity of gemcitabine was signifi-
cantly lower in the nonsmoker group than in the smoker group 
(0.59 mg/m2 versus 0.68 mg/m2; p = 0.03), indicating that dose 
reduction was more common in nonsmokers versus smokers, 
presumably necessitated by treatment-related neutropenia. The 
exact mechanism behind this inverse correlation identified by 
Kanai et al.92 is unclear. In our retrospective study of gem-
citabine in 151 patients, albeit in mixed solid tumors, smok-
ers had less neutropenia than nonsmokers, a finding that was 
more pronounced with increasing pack-years.48 A steep dose-
response curve for gemcitabine is not seen in lung cancer as 
in many other solid tumors. However, there is both preclinical 
and clinical data to support the premise that higher doses are 
associated with greater responses. In a preclinical study by Von 
Hoff,93 a concentration of 22 mcg was associated with higher 
clonogenic cell kill compared with 2 mcg. In a phase I study 
of the 29 patients receiving gemcitabine weekly, treatment 
3 weeks on and 1 week off only seven patients had a clini-
cal response (six at the 2200 mg/m2 dose level and one at the 
2800 mg/m2 dose level).94
In summary, smokers receiving gemcitabine monother-
apy for lung cancer have a lower incidence of grade 3/4 neu-
tropenia compared with nonsmokers; however, the mechanism 
remains unclear. Whether this PD end point is associated with 
clinically meaningful difference in response to gemcitabine in 
humans requires further investigation.
PLATINUM-BASED REGIMENS
Components in smoke can block induced apoptosis 
or promote cellular proliferation54 limiting the efficacy of 
key first-line lung cancer agents, such as cisplatin or carbo-
platin. It is generally accepted that DNA damage and subse-
quent induction of apoptosis may be the primary cytotoxic 
mechanism of platinum compounds. They are used as first-
line chemotherapy for lung cancers. These drugs are primar-
ily excreted renally unchanged, thus suffer no PK alterations 
by compounds in smoke; however, the cellular response to 
platinum-based agents can be altered by smoking status. As 
mentioned above, nicotine can block activation of apoptotic 
pathways such as caspase-9, translocation of Bax or phos-
phorylation of Bad and Bcl-2 in cell lines. Other compounds, 
such as NNKs, can reduce expression of proapoptoic fac-
tors such as Bcl2.56 Nicotine or nicotine-derived nitrosamine 
ketone can antagonize the therapeutic efficacy of cisplatin and 
carboplatin regimens by directly blocking apoptosis.
In addition, cigarette smoke carcinogens have been 
shown to alter expression of key genes involved in platinum-
induced apoptosis through DNA methylation. Studies have 
shown that the expression of DNA methylating enzymes (DNA 
methyltransferases) can be modified in response to cigarette 
smoking.95 In particular, micro RNA, mIR-143, that regulates 
DNTMT3A has been shown to be downregulated in NSCLC 
and associated with smoking status.96 Smoking-induced altera-
tions to DNA methylation of key apoptotic genes can limit the 
efficacy of cisplatin and carboplatin. Consider the human high 
temperature requirement factor A3 (HtrA3), a mitochondrial 
stressed-induced serine protease, which has been described as 
a key factor in modulating sensitivity to cisplatin in smoking-
related lung cancer.97 NNKs can regulate HtrA3 expression 
through exon 1 methylation. Beleford et al.97 demonstrated 
that HtrA3 expression is reduced or absent in over 50% of 
lung cancer cell lines and primary lung tumors from heavy 
smokers. Treatment of HtrA3-deficient cell lines with 5-aza-
2’-deoxycytidine, a DNA methyltransferase inhibitor, resulted 
in a dose-dependent increase in HtrA3 transcription. further 
sequence analysis of bisulfite-modified DNA from lung can-
cer cell lines and primary lung tumors showed an increased 
frequency of methylation within the first exon of HtrA3 with a 
corresponding loss of expression, particularly in tumors from 
smokers. Resistance to cisplatin cytotoxicity was a functional 
consequence of HtrA3 loss because of altered methylation.98 
The study also demonstrated similar findings for the topoi-
somerase inhibitor, etoposide. There are currently no human 
studies demonstrating the clinical relevance of these epigen-
etic effects of smoking on platinum activity.
EFFECTS OF NICOTINE AND NICOTINE 
REPLACEMENT THERAPIES ON METABOLISM 
OF SYSTEMIC THERAPIES FOR LUNG CANCER
Given the increase in prescriptions for various forms of 
nicotine replacement therapies, we looked for studies address-
ing any PK interactions between these and systemic chemo-
therapy for lung cancer. Nicotine is extensively metabolized 
in the liver by several enzymes including the cytochrome 
eP450 system (CYP2A6), aldehyde oxidases and uridine 
5′-diphosphate-glucuronyl transferases. Various drugs that 
use these metabolic pathways can have an effect on nicotine 
metabolism as reviewed by Hukkanen et al.99 However, there 
are no human trials evaluating PK interactions between nico-
tine replacement therapies and systemic therapies used to treat 
lung cancer. Varenicline, a partial agonist at nicotinic acetyl-
choline receptors, is widely used and a successful smoking 
cessation aid. Preclinical studies showed a high affinity of 
varenicline for 5HT3 receptors.100 5-HT
3
 receptor antagonists 
are in use clinically, primarily for controlling chemotherapy- 
and radiotherapy-induced nausea and vomiting. However, it is 
unclear whether this results in clinically relevant drug interac-
tions. There are no reported studies of interactions between 
varenicline and often used systemic therapies for lung cancer
CONCLUSION AND SUMMARY
Cigarette smoking is an independent factor relating to 
poor outcomes after a diagnosis of lung cancer. Herein, we 
reviewed the literature for the effects of smoking on often 
used systemic therapy for lung cancer. Admittedly, there are 
multiple biological reasons for variable PK/PD effects related 
to smoking and systemic cancer therapy effects. Results from 
preclinical experiments have not been rigorously studied in 
clinical settings. We primarily addressed potential differences 
in drug metabolism in smokers versus nonsmokers. Other fac-
tors include inherent biological differences in smoking-related 
cancers that are well described, such as presence of specific 
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mutations (e.g., Kras), decreased apoptotic potential, or highly 
complex heterogeneous tumors that do not lend themselves to 
effective cell kill from current therapies. Host factors in smok-
ers may include a complex interplay with polymorphisms in 
common metabolizing enzymes, and impairments in absorp-
tion, distribution, and excretion of specific systemic therapies. 
These limitations notwithstanding, it is apparent that smoking 
leads to accelerated clearance of specific systemic therapies.
The question arises whether an increase in dose of 
systemic therapies for lung cancer will result in a clinically 
significant difference in response or overall outcomes. There 
is a paucity of data specifically addressing a dose-response 
effect of lung cancer specific systemic therapies in smok-
ers. There are no prospective studies that specifically link 
smoking-mediated induction of drug metabolism to therapy 
efficacy. Although this phenomenon is fairly well described 
in the literature for non-chemotherapy medications, the data 
investigating the effect on chemotherapy drugs are limited 
and primarily restricted to retrospective data and PK stud-
ies. It can be posited that reduced concentrations of systemic 
therapy related to increased catabolism may lead to reduced 
efficacy of the drug in former smokers. Therefore, smokers 
(including smokers who recently quit) may then require a 
higher therapy dose overcome the likelihood of accelerated 
catabolism. PK parameters should be studied, particularly in 
former smokers. Whether individualized chemotherapy dose 
algorithms according to metabolic phenotype and smoking 
history will impact patient outcomes remains to be seen. Thus, 
prospective trials comparing chemotherapy PKs in smokers 
versus nonsmokers are required. Similarly, although there is 
preclinical data to suggest that nicotine itself is proliferative 
and antiapoptotic in cell culture systems, prospective trials are 
needed to determine whether nicotine (including replacement 
cessation therapies) can lead to interactions with often used 
systemic therapies for lung cancer which may limit therapeu-
tic efficacy.
In summary, PK and PD interactions between cigarette 
smoking and chemotherapy drugs may significantly impact 
drug clearance, delivery, toxicity, and efficacy. Cigarette 
smoking history must be carefully considered as a patient-
specific factor capable of impacting treatment and potentially 
disease outcome. Smoking cessation must be emphasized 
at every clinical encounter.101,102 However, in former smok-
ers, dysregulation of drug-metabolizing enzymes may per-
sist and potentially leading to increased clearance. These are 
the patients who will benefit from additional well-conducted 
clinical trials. findings could yield potential therapeutic tar-
gets that could be modulated according to histone acetylation 
or DNA methylation status, particularly if epigenetic effects 
are responsible for keeping these metabolizing enzymes in a 
persistently activated state. Optimally, clinical trials should 
take this factor into consideration and potentially use smoking 
status as an independent predictive variable when designing 
studies of personalized medicine.
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